SK7342000A3 - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine Download PDF

Info

Publication number: SK7342000A3
Authority: SK; Slovakia
Prior art keywords: paroxetine; solid; capsules; carrier; capsule
Prior art date: 1997-11-21

Application number

SK734-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ahmad Ghazawi

Graham Stanley Leonard

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-21

Filing date

1998-11-18

Publication date

2000-12-11

1998-11-18 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-12-11 Publication of SK7342000A3 publication Critical patent/SK7342000A3/sk

Links

AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 214
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims abstract description 112
229960002296 paroxetine Drugs 0.000 title claims abstract description 111
239000000203 mixture Substances 0.000 title claims description 23
238000009472 formulation Methods 0.000 title claims description 16
239000002775 capsule Substances 0.000 claims abstract description 90
239000000243 solution Substances 0.000 claims abstract description 55
239000007787 solid Substances 0.000 claims abstract description 42
239000007788 liquid Substances 0.000 claims abstract description 25
239000007909 solid dosage form Substances 0.000 claims abstract description 24
239000008188 pellet Substances 0.000 claims abstract description 14
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
239000006104 solid solution Substances 0.000 claims abstract description 11
239000003921 oil Substances 0.000 claims abstract description 7
150000002632 lipids Chemical class 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
239000002904 solvent Substances 0.000 claims description 62
229960005183 paroxetine hydrochloride Drugs 0.000 claims description 56
239000000499 gel Substances 0.000 claims description 36
239000003826 tablet Substances 0.000 claims description 27
-1 spheroids Substances 0.000 claims description 20
238000000576 coating method Methods 0.000 claims description 12
239000008187 granular material Substances 0.000 claims description 11
230000009747 swallowing Effects 0.000 claims description 10
230000002209 hydrophobic effect Effects 0.000 claims description 9
239000011248 coating agent Substances 0.000 claims description 8
239000012458 free base Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
150000008064 anhydrides Chemical class 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
239000003925 fat Substances 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
206010036618 Premenstrual syndrome Diseases 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
229940100691 oral capsule Drugs 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
208000007848 Alcoholism Diseases 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 3
208000032841 Bulimia Diseases 0.000 claims description 3
206010006550 Bulimia nervosa Diseases 0.000 claims description 3
208000000094 Chronic Pain Diseases 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
208000008589 Obesity Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
206010039966 Senile dementia Diseases 0.000 claims description 3
206010041250 Social phobia Diseases 0.000 claims description 3
201000007930 alcohol dependence Diseases 0.000 claims description 3
208000022531 anorexia Diseases 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
206010061428 decreased appetite Diseases 0.000 claims description 3
208000024732 dysthymic disease Diseases 0.000 claims description 3
230000009969 flowable effect Effects 0.000 claims description 3
239000007937 lozenge Substances 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
235000020824 obesity Nutrition 0.000 claims description 3
229920001169 thermoplastic Polymers 0.000 claims description 3
239000001993 wax Substances 0.000 claims description 3
230000000873 masking effect Effects 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000012453 solvate Substances 0.000 claims description 2
201000009032 substance abuse Diseases 0.000 claims description 2
231100000736 substance abuse Toxicity 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims 1
239000011345 viscous material Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 15
239000012669 liquid formulation Substances 0.000 abstract description 3
239000012051 hydrophobic carrier Substances 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 39
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 22
229920000053 polysorbate 80 Polymers 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
229940079593 drug Drugs 0.000 description 17
239000003814 drug Substances 0.000 description 17
229920000159 gelatin Polymers 0.000 description 17
235000019322 gelatine Nutrition 0.000 description 17
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 16
229920000642 polymer Polymers 0.000 description 14
239000006184 cosolvent Substances 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
239000000463 material Substances 0.000 description 12
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 12
229940068968 polysorbate 80 Drugs 0.000 description 12
239000001828 Gelatine Substances 0.000 description 11
125000005456 glyceride group Chemical group 0.000 description 11
239000008213 purified water Substances 0.000 description 11
239000000969 carrier Substances 0.000 description 10
235000010323 ascorbic acid Nutrition 0.000 description 9
239000011668 ascorbic acid Substances 0.000 description 9
229960005070 ascorbic acid Drugs 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000000473 propyl gallate Substances 0.000 description 8
235000010388 propyl gallate Nutrition 0.000 description 8
229940075579 propyl gallate Drugs 0.000 description 8
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 7
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 6
235000019197 fats Nutrition 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
239000004166 Lanolin Substances 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000003240 coconut oil Substances 0.000 description 5
235000019864 coconut oil Nutrition 0.000 description 5
235000019388 lanolin Nutrition 0.000 description 5
229940039717 lanolin Drugs 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229940068918 polyethylene glycol 400 Drugs 0.000 description 5
235000019483 Peanut oil Nutrition 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
238000005538 encapsulation Methods 0.000 description 4
230000037406 food intake Effects 0.000 description 4
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000312 peanut oil Substances 0.000 description 4
229920001983 poloxamer Polymers 0.000 description 4
239000003549 soybean oil Substances 0.000 description 4
235000012424 soybean oil Nutrition 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
235000019486 Sunflower oil Nutrition 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000001816 cooling Methods 0.000 description 3
235000012343 cottonseed oil Nutrition 0.000 description 3
239000002385 cottonseed oil Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
229960002216 methylparaben Drugs 0.000 description 3
239000000047 product Substances 0.000 description 3
239000002600 sunflower oil Substances 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 2
LPYUENQFPVNPHY-UHFFFAOYSA-N 3-methoxycatechol Chemical compound COC1=CC=CC(O)=C1O LPYUENQFPVNPHY-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
239000011627 DL-alpha-tocopherol Substances 0.000 description 2
RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 2
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000003490 Thiodipropionic acid Substances 0.000 description 2
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000000555 dodecyl gallate Substances 0.000 description 2
235000010386 dodecyl gallate Nutrition 0.000 description 2
229940080643 dodecyl gallate Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
229940074391 gallic acid Drugs 0.000 description 2
235000004515 gallic acid Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
239000001087 glyceryl triacetate Substances 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000002563 ionic surfactant Substances 0.000 description 2
HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000007909 melt granulation Methods 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000000574 octyl gallate Substances 0.000 description 2
235000010387 octyl gallate Nutrition 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
235000014593 oils and fats Nutrition 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000003002 pH adjusting agent Substances 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
SNGARVZXPNQWEY-UHFFFAOYSA-N phenylmethanediol Chemical compound OC(O)C1=CC=CC=C1 SNGARVZXPNQWEY-UHFFFAOYSA-N 0.000 description 2
238000000053 physical method Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
235000011067 sorbitan monolaureate Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003860 storage Methods 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
235000019303 thiodipropionic acid Nutrition 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
229960002622 triacetin Drugs 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
ZSVWTKSPCSYFBN-UHFFFAOYSA-N 4-[3-(3,4-dihydroxyphenyl)-2,3-dimethylbutan-2-yl]benzene-1,2-diol Chemical compound C=1C=C(O)C(O)=CC=1C(C)(C)C(C)(C)C1=CC=C(O)C(O)=C1 ZSVWTKSPCSYFBN-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
239000004063 acid-resistant material Substances 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000010477 apricot oil Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
ZITKDVFRMRXIJQ-UHFFFAOYSA-N dodecane-1,2-diol Chemical compound CCCCCCCCCCC(O)CO ZITKDVFRMRXIJQ-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
RRQQLCXFGWWLPQ-UHFFFAOYSA-N ethanol;octadecan-1-amine Chemical compound CCO.CCCCCCCCCCCCCCCCCCN RRQQLCXFGWWLPQ-UHFFFAOYSA-N 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
235000008524 evening primrose extract Nutrition 0.000 description 1
239000010475 evening primrose oil Substances 0.000 description 1
229940089020 evening primrose oil Drugs 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000007757 hot melt coating Methods 0.000 description 1
239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
239000010512 hydrogenated peanut oil Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
229940049918 linoleate Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960003951 masoprocol Drugs 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000000178 monomer Substances 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229920003168 pharmaceutical polymer Polymers 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229920000059 polyethylene glycol stearate Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229940024463 silicone emollient and protective product Drugs 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

SK734-2000A 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine SK7342000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9724544.3A GB9724544D0 (en)	1997-11-21	1997-11-21	Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (fr)	1997-11-21	1998-11-18	Formulations contenant de la paroxetine dissoute

Publications (1)

Publication Number	Publication Date
SK7342000A3 true SK7342000A3 (en)	2000-12-11

Family

ID=10822374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK734-2000A SK7342000A3 (en)	1997-11-21	1998-11-18	Formulations comprising dissolved paroxetine

Country Status (24)

Country	Link
EP (1)	EP1033986A1 (fr)
JP (1)	JP2001523718A (fr)
KR (1)	KR20010032320A (fr)
CN (1)	CN1279608A (fr)
AP (1)	AP2000001821A0 (fr)
AR (1)	AR015485A1 (fr)
AU (1)	AU1168099A (fr)
BG (1)	BG104527A (fr)
BR (1)	BR9814220A (fr)
CO (1)	CO4970832A1 (fr)
DZ (1)	DZ2658A1 (fr)
EA (1)	EA200000552A1 (fr)
GB (1)	GB9724544D0 (fr)
HU (1)	HUP0100580A3 (fr)
IL (1)	IL136106A0 (fr)
MA (1)	MA24704A1 (fr)
NO (1)	NO20002590L (fr)
OA (1)	OA11385A (fr)
PE (1)	PE20000381A1 (fr)
PL (1)	PL340555A1 (fr)
SK (1)	SK7342000A3 (fr)
TR (1)	TR200001423T2 (fr)
WO (1)	WO1999026625A1 (fr)
ZA (1)	ZA9810637B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9810180D0 (en) *	1998-05-13	1998-07-08	Smithkline Beecham Plc	Novel formulation
WO2000054775A1 (fr) *	1999-03-12	2000-09-21	Basf Ag	Forme galenique pharmaceutique stable pour anhydrate de paroxetine
DE60004768T2 (de)	1999-07-01	2004-07-08	Italfarmaco S.P.A.	Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
DE19930454A1 (de) *	1999-07-02	2001-01-04	Knoll Ag	Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en)	2001-02-16	2004-04-13	Andrx Corporation	Serotonin reuptake inhibitor formulations
US7011846B2 (en) *	2001-12-21	2006-03-14	Shire Laboratories, Inc.	Oral capsule formulation with increased physical stability
SE0200475D0 (sv) *	2002-02-15	2002-02-15	Ltp Lipid Technologies Provide	Oral farmaceutisk beredning
WO2006119779A2 (fr) *	2005-05-10	2006-11-16	Lifecycle Pharma A/S	Composition pharmaceutique comprenant un antagoniste de l'aldosterone
JP2013512948A (ja) *	2009-12-08	2013-04-18	イル・ファ・カンパニー・リミテッド	２０−Ｏ−β−Ｄ−グルコピラノシル−２０（Ｓ）−プロトパナキサジオールを含む固体分散体
GB201020032D0 (en) *	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
CN103961333B (zh) *	2014-05-07	2020-02-21	浙江华海药业股份有限公司	甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996031197A1 (fr) *	1995-04-03	1996-10-10	Abbott Laboratories	Melanges homogenes de medicaments fondant a basse temperature et d'additifs, destines a une liberation lente
HUP0000960A3 (en) *	1997-01-15	2001-04-28	Smithkline Beecham Plc	Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

1997
- 1997-11-21 GB GBGB9724544.3A patent/GB9724544D0/en not_active Ceased
1998
- 1998-11-18 AU AU11680/99A patent/AU1168099A/en not_active Abandoned
- 1998-11-18 PL PL98340555A patent/PL340555A1/xx unknown
- 1998-11-18 EP EP98954631A patent/EP1033986A1/fr not_active Withdrawn
- 1998-11-18 PE PE1998001126A patent/PE20000381A1/es not_active Application Discontinuation
- 1998-11-18 AP APAP/P/2000/001821A patent/AP2000001821A0/en unknown
- 1998-11-18 DZ DZ980268A patent/DZ2658A1/fr active
- 1998-11-18 WO PCT/GB1998/003471 patent/WO1999026625A1/fr not_active Ceased
- 1998-11-18 CN CN98811404A patent/CN1279608A/zh active Pending
- 1998-11-18 JP JP2000521827A patent/JP2001523718A/ja active Pending
- 1998-11-18 EA EA200000552A patent/EA200000552A1/ru unknown
- 1998-11-18 HU HU0100580A patent/HUP0100580A3/hu unknown
- 1998-11-18 IL IL13610698A patent/IL136106A0/xx unknown
- 1998-11-18 TR TR2000/01423T patent/TR200001423T2/xx unknown
- 1998-11-18 KR KR1020007005532A patent/KR20010032320A/ko not_active Withdrawn
- 1998-11-18 BR BR9814220-8A patent/BR9814220A/pt not_active Application Discontinuation
- 1998-11-18 SK SK734-2000A patent/SK7342000A3/sk unknown
- 1998-11-19 MA MA25357A patent/MA24704A1/fr unknown
- 1998-11-19 AR ARP980105880A patent/AR015485A1/es unknown
- 1998-11-20 CO CO98068459A patent/CO4970832A1/es unknown
- 1998-11-20 ZA ZA9810637A patent/ZA9810637B/xx unknown
2000
- 2000-05-19 OA OA1200000153A patent/OA11385A/en unknown
- 2000-05-19 NO NO20002590A patent/NO20002590L/no not_active Application Discontinuation
- 2000-06-13 BG BG104527A patent/BG104527A/xx unknown

Also Published As

Publication number	Publication date
EA200000552A1 (ru)	2000-10-30
AP2000001821A0 (en)	2000-06-30
KR20010032320A (ko)	2001-04-16
PL340555A1 (en)	2001-02-12
AU1168099A (en)	1999-06-15
NO20002590D0 (no)	2000-05-19
CN1279608A (zh)	2001-01-10
OA11385A (en)	2004-01-27
TR200001423T2 (tr)	2000-10-23
IL136106A0 (en)	2001-05-20
WO1999026625A1 (fr)	1999-06-03
CO4970832A1 (es)	2000-11-07
BG104527A (en)	2001-04-30
BR9814220A (pt)	2001-12-26
NO20002590L (no)	2000-07-19
ZA9810637B (en)	2000-05-22
HUP0100580A2 (hu)	2002-04-29
DZ2658A1 (fr)	2003-03-22
MA24704A1 (fr)	1999-07-01
PE20000381A1 (es)	2000-05-07
JP2001523718A (ja)	2001-11-27
EP1033986A1 (fr)	2000-09-13
AR015485A1 (es)	2001-05-02
HUP0100580A3 (en)	2002-05-28
GB9724544D0 (en)	1998-01-21

Publication	Publication Date	Title
US6524615B2 (en)	2003-02-25	Controlled release pharmaceutical composition
US6491950B1 (en)	2002-12-10	Controlled release pharmaceutical composition
US6372251B2 (en)	2002-04-16	Formulations comprising lipid-regulating agents
US8293270B2 (en)	2012-10-23	Lipophilic vehicle-based dual controlled release matrix system
CA2365128A1 (fr)	2000-10-05	Preparations contenant des agents regulateurs de lipides
WO2021163023A1 (fr)	2021-08-19	Formulations stables de dronabinol
KR100679582B1 (ko)	2007-02-07	경질 쉘 캡슐용 이부프로펜 용액
SK7342000A3 (en)	2000-12-11	Formulations comprising dissolved paroxetine
US6838091B2 (en)	2005-01-04	Formulations comprising lipid-regulating agents
EP1183017A1 (fr)	2002-03-06	Formulations comprenant des agents regulateurs des lipides
KR20040006887A (ko)	2004-01-24	아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US6814977B1 (en)	2004-11-09	Formulations comprising lipid-regulating agents
US20020032220A1 (en)	2002-03-14	Formulations comprising dissolved paroxetine
US20040146537A1 (en)	2004-07-29	Oily wax matrix suspension formulation comprising pharmacologically active agents
US20020040046A1 (en)	2002-04-04	Novel formulations comprising lipid-regulating agents
CZ20001876A3 (cs)	2001-01-17	Prostředky obsahující rozpuštěný paroxetin
MXPA00005030A (en)	2001-05-07	Formulations comprising dissolved paroxetine
CA2310407A1 (fr)	1999-06-03	Formulations contenant de la paroxetine dissoute
SI8710407A (sl)	1996-08-31	Postopek za pridobivanje trdnega pripravka s podaljšanim sproščanjem aktivne spojine